Prognostic impact of hyperdiploidy in multiple myeloma patients with high-risk cytogenetics: a pilot study in China

Mei, Jian-Gang; Zhai, Yong‐Ping; Li, Hanqing; Li, Feng; Zhao, Xiaogang; Song, Peng; Zhao, Qian; Yu, Yang; An, Zhi-Ming; Wang, Liping

doi:10.1007/s00432-018-2732-3

Cited by 13 publications

(14 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The median follow-up period was 25 months (IQR: . The median age at diagnosis was 57 years (IQR: 51-64), which was similar to other recent studies of Chinese MM patients (19)(20)(21)(22). According to ISS, 57% (70/123) patients were at stage III.…”

Section: Patient Characteristicssupporting

confidence: 87%

Partial immunoparesis contributes to risk of early infections in patients with multiple myeloma

Huang¹,

Wei²,

Wei³

et al. 2021

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background Partial immunoparesis, which means at least two suppressed uninvolved immunoglobulins (Igs), had been reported to be associated with poor prognosis in patients with multiple myeloma (MM), but the impact on early infections remains unknown. The purpose of our study was to determine the prognostic implications of partial immunoparesis on early grade ≥3 infections in patients with MM. Methods Herein we retrospectively analyzed the clinical data of 123 MM patients between 2012 and 2020 at Nanfang Hospital. All patients received bortezomib-based regimens. The relationship between early grade ≥3 infections and partial immunoparesis was investigated using Cox regression analysis. Results Our data showed partial immunoapresis was found in 63% MM patients. Partial immunoparesis was significantly related to elevated beta-2-microglobulin (B2M), decreased estimated glomerular filtration rate (eGFR) and progressive international staging system (ISS) stage (P<0.05). Especially, univariate Cox regression analysis showed partial immunoparesis was significantly correlated with early grade ≥3 infections (P=0.003). Moreover, multivariate Cox regression analysis showed partial immunoparesis was an independent significant prognostic factor for early grade ≥3 infections [odds ratio (OR) =3.048; 95% confidence interval (CI): 1.429–6.504; P=0.004]. Furthermore, partial immunoapresis could improve the infection risk model built by Dumontet et al. Conclusions Our study showed that partial immunoparesis could predict early infections in patients with MM, which may be used to identify the high risk patients for infections and guide strategies for infection prevention.

show abstract

Section: Patient Characteristicssupporting

confidence: 87%

Partial immunoparesis contributes to risk of early infections in patients with multiple myeloma

Huang¹,

Wei²,

Wei³

et al. 2021

Transl Cancer Res TCR

View full text Add to dashboard Cite

show abstract

“…Overall, hyperdiploidy seems to confer a neutral or inferior outcome in AL patients, which is contradictory to results from MM studies that indicate a favorable prognostic effect of hyperdiploidy [ 12 , 13 , 60 ]. The transferability of the classically defined hyperdiploidy in the iFISH method, previously used in MM, to AL remains uncertain, and further studies are needed to define and validate the criteria of hyperdiploidy in AL based on the iFISH method.…”

Section: Hyperdiploidycontrasting

confidence: 71%

Genetic pathogenesis of immunoglobulin light chain amyloidosis: basic characteristics and clinical applications

2021

Exp Hematol Oncol

View full text Add to dashboard Cite

Immunoglobulin light chain amyloidosis (AL) is an indolent plasma cell disorder characterized by free immunoglobulin light chain (FLC) misfolding and amyloid fibril deposition. The cytogenetic pattern of AL shows profound similarity with that of other plasma cell disorders but harbors distinct features. AL can be classified into two primary subtypes: non-hyperdiploidy and hyperdiploidy. Non-hyperdiploidy usually involves immunoglobulin heavy chain translocations, and t(11;14) is the hallmark of this disease. T(11;14) is associated with low plasma cell count but high FLC level and displays distinct response outcomes to different treatment modalities. Hyperdiploidy is associated with plasmacytosis and subclone formation, and it generally confers a neutral or inferior prognostic outcome. Other chromosome abnormalities and driver gene mutations are considered as secondary cytogenetic aberrations that occur during disease evolution. These genetic aberrations contribute to the proliferation of plasma cells, which secrete excess FLC for amyloid deposition. Other genetic factors, such as specific usage of immunoglobulin light chain germline genes and light chain somatic mutations, also play an essential role in amyloid fibril deposition in AL. This paper will propose a framework of AL classification based on genetic aberrations and discuss the amyloid formation of AL from a genetic aspect.

show abstract

“…Several studies have shown that hyperdiploid patients have better response rates to treatment and longer survival than patients with other aneuploidies [87]. This favorable prognosis was observed irrespective of the therapeutic context [88][89][90]. However, not all trisomies have the same impact on survival; in particular, trisomies of chromosomes 3 and 5 improve the prognosis in patients treated with chemotherapy or bortezomib followed by ASCT, and also in those treated with non-intensive protocols, even in patients with t(4;14) [91].…”

Section: Prognosismentioning

confidence: 98%

Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications

Cardona‐Benavides

Ramón

Gutiérrez

2021

Cells

View full text Add to dashboard Cite

Some genetic abnormalities of multiple myeloma (MM) detected more than two decades ago remain major prognostic factors. In recent years, the introduction of cutting-edge genomic methodologies has enabled the extensive deciphering of genomic events in MM. Although none of the alterations newly discovered have significantly improved the stratification of the outcome of patients with MM, some of them, point mutations in particular, are promising targets for the development of personalized medicine. This review summarizes the main genetic abnormalities described in MM together with their prognostic impact, and the therapeutic approaches potentially aimed at abrogating the undesirable pathogenic effect of each alteration.

show abstract

Prognostic impact of hyperdiploidy in multiple myeloma patients with high-risk cytogenetics: a pilot study in China

Abstract: These results suggest that the coexistence of hyperdiploidy may ameliorate the adverse prognosis of multiple myeloma patients with high-risk cytogenetics. High-risk cytogenetics patients without hyperdiploidy showed the worst prognosis.

Cited by 13 publications

References 40 publications

Partial immunoparesis contributes to risk of early infections in patients with multiple myeloma

Partial immunoparesis contributes to risk of early infections in patients with multiple myeloma

Genetic pathogenesis of immunoglobulin light chain amyloidosis: basic characteristics and clinical applications

Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications

Contact Info

Product

Resources

About